Ambien CR Generics Need Extra Bioequivalence Tests, Sanofi Argues To FDA
Executive Summary
Sanofi-Aventis is requesting that FDA require additional bioequivalence tests for generic versions of its insomnia product Ambien CR (zolpidem extended-release)